Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium)
Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium)
RPP: Abs

Request for Project Proposals for Antibody (Ab) Advanced Manufacturing Capability Improvement: Smart Technologies

Building on the proven performance of Abs for rapid response, the U.S. government is seeking innovative solutions to strengthen domestic preparedness against threats such as anthrax, Ebola, RSV, and SARS-CoV-2. This effort focuses on advancing technologies that improve the speed, efficiency, and resilience of Ab production.

Submissions Due: Oct. 1, 2025 at 1 p.m. ET

Key Events: 
Solicitation Webinar: Mon., Sept. 15, 2–3 p.m. ET
Teaming Speed Networking Event: Tues., Sept. 16, 1 p.m. ET
Intro Slide

Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium)

Strengthening and enhancing domestic
biopharmaceutical manufacturing capabilities
previous arrow
next arrow

Get involved!

Seeking partnerships to rapidly respond to future Public Health Emergencies (PHE)

Member Benefits:

No Cost Barrier for Entry

Pre-negotiated Terms

Fast & Flexible Partnerships

Networking & Engagement with Industry

Industrial Base Expansion of Supply Chain

Engage with the network of organizations and personnel that provide all goods and services in support of the entire biomanufacturing process, to include, but not limited to, raw materials, consumables, and fill-finish services.

Biomanufacturing Capacity Expansion and Reservation

Prepare and provide timely, integrated, and sufficient medical countermeasures in response to emerging pathogens with pandemic potential through establishing, expanding and/or reserving drug substance and/or drug product manufacturing capacities.

Advanced Biomanufacturing Technologies

Address new and emerging technologies, that enhance existing capabilities that increase the speed, quality, safety, yield, efficiency of the biomanufacturing process or the safety, quality, effectiveness, or availability of the resulting biopharmaceutical drug product.